Kasabach-Merritt syndrome natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Kasabach-Merritt syndrome}} {{CMG}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==O...") |
No edit summary |
||
Line 9: | Line 9: | ||
They are at risk of bleeding complications including [[intracranial hemorrhage]]. The thrombocytopenia and coagulopathy are managed with platelet transfusions and [[fresh frozen plasma]], although caution is needed due to the risk of [[fluid overload]] and [[heart failure]] from multiple transfusions. The possibility of [[disseminated intravascular coagulation]], a dangerous and difficult-to-manage condition, is concerning. [[Anticoagulant]] and antiplatelet medications can be used after careful assessment of the risks and benefits. | They are at risk of bleeding complications including [[intracranial hemorrhage]]. The thrombocytopenia and coagulopathy are managed with platelet transfusions and [[fresh frozen plasma]], although caution is needed due to the risk of [[fluid overload]] and [[heart failure]] from multiple transfusions. The possibility of [[disseminated intravascular coagulation]], a dangerous and difficult-to-manage condition, is concerning. [[Anticoagulant]] and antiplatelet medications can be used after careful assessment of the risks and benefits. | ||
==Prognosis== | ==Prognosis== | ||
Patients with KMS can be extremely ill and may need [[intensive care]]. | Patients with KMS can be extremely ill and may need [[intensive care]]. KMS has a mortality rate of about 30%. For patients that survive the acute disease, supportive care may be required through a gradual recovery. | ||
Furthermore, patients may need care from a [[dermatologist]] or [[plastic surgeon]] for residual cosmetic lesions. On long-term followup, most patients have skin discoloration and/or mild disfiguration from the dormant tumor.<ref name="Enjolras2000">{{cite journal | |||
| author=Enjolras O, Mulliken J, Wassef M, Frieden I, Rieu P, Burrows P, Salhi A, Léauté-Labrèze C, Kozakewich H | |||
| title=Residual lesions after Kasabach-Merritt phenomenon in 41 patients. | |||
| journal=J Am Acad Dermatol | |||
| volume=42 | |||
| issue=2 Pt 1 | |||
| pages=225-35 | |||
| year=2000 | |||
| id=PMID 10642677}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Latest revision as of 17:24, 21 September 2012
Kasabach-Merritt syndrome Microchapters |
Differentiating Kasabach-Merritt syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Kasabach-Merritt syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Kasabach-Merritt syndrome natural history, complications and prognosis |
FDA on Kasabach-Merritt syndrome natural history, complications and prognosis |
CDC on Kasabach-Merritt syndrome natural history, complications and prognosis |
Kasabach-Merritt syndrome natural history, complications and prognosis in the news |
Blogs on Kasabach-Merritt syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Natural History
Complications
They are at risk of bleeding complications including intracranial hemorrhage. The thrombocytopenia and coagulopathy are managed with platelet transfusions and fresh frozen plasma, although caution is needed due to the risk of fluid overload and heart failure from multiple transfusions. The possibility of disseminated intravascular coagulation, a dangerous and difficult-to-manage condition, is concerning. Anticoagulant and antiplatelet medications can be used after careful assessment of the risks and benefits.
Prognosis
Patients with KMS can be extremely ill and may need intensive care. KMS has a mortality rate of about 30%. For patients that survive the acute disease, supportive care may be required through a gradual recovery.
Furthermore, patients may need care from a dermatologist or plastic surgeon for residual cosmetic lesions. On long-term followup, most patients have skin discoloration and/or mild disfiguration from the dormant tumor.[1]
References
- ↑ Enjolras O, Mulliken J, Wassef M, Frieden I, Rieu P, Burrows P, Salhi A, Léauté-Labrèze C, Kozakewich H (2000). "Residual lesions after Kasabach-Merritt phenomenon in 41 patients". J Am Acad Dermatol. 42 (2 Pt 1): 225–35. PMID 10642677.